![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Sucampo’s Reflux Disease Drug Fails in Phase 2
Sucampo’s Reflux Disease Drug Fails in Phase 2
April 25, 2016
Sucampo Pharmaceuticals is halting the development of cobiprostone in certain types of reflux disease after the candidate failed to impress in a Phase 2a trial.
The study was evaluating the candidate in patients with proton pump inhibitor-refractory non-erosive reflux disease or symptomatic gastroesophageal reflux disease. However, it failed to meaningfully reduce heartburn symptoms.
Cobiprostone is being developed for the prevention of oral mucositis in head and neck cancer patients receiving radiation and chemotherapy.
Upcoming Events
-
21Oct